Genetically modified natural killer (NK) cells to treat glioblastoma

Glioblastoma is the most common malignant brain tumor in adults, and current treatment options are extremely limited and often ineffective, leading to the death of most patients within 12-18 months of diagnosisRecently, researchers at Purdue University in the United States have developed a promising new method, using natural killer (NK) cells to treat glioblastoma, and researchers have genetically modified NK cells to accurately target and kill cancer cells"Multi-functional modification of NK cells is a potential way to improve treatments," said Sandro Matosevic, an assistant professor at Purdue University School of Medicine inThe challenge in developing a therapy for GBM (polymorphic glioblastoma) is that the disease has a high degree ofimmunosuppressive, and many of the treatments developed for GBM use a variety of mechanisms to evade immune system recognition, so many of the therapies developed for it have not been successfulGBM is the most aggressive brain tumorAlthough there are a variety of intensive therapies (surgery, chemotherapy and radiotherapy) to choose from, patients with GBM rarely survive for more than 15 months, and none of them can be curedThis is because most drugs work in a single way, while GBM uses highly complex immunosuppressive mechanisms to increase resistance to treatment and evade immune identification